Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1213 to 1216 of 1216 entries
Sorted by: Best Match Show Resources per page
Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90.

European journal of medical genetics

Narayanan DL, Majethia P, Shrikiran A, Siddiqui S, Dalal A, Shukla A.
PMID: 34871784
Eur J Med Genet. 2021 Dec 04;65(1):104403. doi: 10.1016/j.ejmg.2021.104403. Epub 2021 Dec 04.

Developmental and epileptic encephalopathies (DEE) are a genetically heterogeneous group of disorders characterised by early onset epilepsy, epileptiform activity on electroencephalogram and associated developmental delay or neuroregression. With the advent of high throughput sequencing, novel gene-disease associations have been...

Cite
Narayanan DL, Majethia P, Shrikiran A, et al. Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90. Eur J Med Genet. 2021;65(1):104403doi: 10.1016/j.ejmg.2021.104403.
Narayanan, D. L., Majethia, P., Shrikiran, A., Siddiqui, S., Dalal, A., & Shukla, A. (2021). Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90. European journal of medical genetics, 65(1), 104403. https://doi.org/10.1016/j.ejmg.2021.104403
Narayanan, Dhanya Lakshmi, et al. "Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90." European journal of medical genetics vol. 65,1 (2021): 104403. doi: https://doi.org/10.1016/j.ejmg.2021.104403
Narayanan DL, Majethia P, Shrikiran A, Siddiqui S, Dalal A, Shukla A. Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90. Eur J Med Genet. 2021 Dec 04;65(1):104403. doi: 10.1016/j.ejmg.2021.104403. Epub 2021 Dec 04. PMID: 34871784.
Copy Download .nbib Format: NLM
Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis.

Journal of cancer epidemiology

Li H, Hodgson E, Watson L, Shukla A, Nelson JJ.
PMID: 22570655
J Cancer Epidemiol. 2012;2012:291704. doi: 10.1155/2012/291704. Epub 2012 Apr 11.

Comorbidity influences screening practice, treatment choice, quality of life, and survival. The presence of comorbidities and medication use could place patients at greater risks of adverse effects from certain interventions. We conducted a longitudinal cohort study in the General...

Cite
Li H, Hodgson E, Watson L, et al. Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis. J Cancer Epidemiol. 2012;2012:291704doi: 10.1155/2012/291704.
Li, H., Hodgson, E., Watson, L., Shukla, A., & Nelson, J. J. (2012). Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis. Journal of cancer epidemiology, 2012291704. https://doi.org/10.1155/2012/291704
Li, Haojie, et al. "Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis." Journal of cancer epidemiology vol. 2012 (2012): 291704. doi: https://doi.org/10.1155/2012/291704
Li H, Hodgson E, Watson L, Shukla A, Nelson JJ. Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis. J Cancer Epidemiol. 2012;2012:291704. doi: 10.1155/2012/291704. Epub 2012 Apr 11. PMID: 22570655; PMCID: PMC3335188.
Copy Download .nbib Format: NLM
Evaluation of decontamination efficacy of electrolytically generated hypochlorous acid for vesicating agent: A multimodel Study.

Current pharmaceutical biotechnology

Sharma AK, Shukla SK, Kalonia A, Shaw P, Khanna K, Gupta R, Yashavarddhan MH, Bhatnagar A.
PMID: 33719970
Curr Pharm Biotechnol. 2021 Mar 11; doi: 10.2174/1389201022666210311140922. Epub 2021 Mar 11.

BACKGROUND: Sulfur Mustard is a strong vesicant and chemical warfare agent that imposes toxicity to the lungs, eyes, and skin after accidental or intended exposure.OBJECTIVES: The current study was intended to explore in vitro and in vivo decontamination properties...

Cite
Sharma AK, Shukla SK, Kalonia A, et al. Evaluation of decontamination efficacy of electrolytically generated hypochlorous acid for vesicating agent: A multimodel Study. Curr Pharm Biotechnol. 2021;doi: 10.2174/1389201022666210311140922.
Sharma, A. K., Shukla, S. K., Kalonia, A., Shaw, P., Khanna, K., Gupta, R., Yashavarddhan, M. H., & Bhatnagar, A. (2021). Evaluation of decontamination efficacy of electrolytically generated hypochlorous acid for vesicating agent: A multimodel Study. Current pharmaceutical biotechnology, . https://doi.org/10.2174/1389201022666210311140922
Sharma, Ajay Kumar, et al. "Evaluation of decontamination efficacy of electrolytically generated hypochlorous acid for vesicating agent: A multimodel Study." Current pharmaceutical biotechnology vol. (2021). doi: https://doi.org/10.2174/1389201022666210311140922
Sharma AK, Shukla SK, Kalonia A, Shaw P, Khanna K, Gupta R, Yashavarddhan MH, Bhatnagar A. Evaluation of decontamination efficacy of electrolytically generated hypochlorous acid for vesicating agent: A multimodel Study. Curr Pharm Biotechnol. 2021 Mar 11; doi: 10.2174/1389201022666210311140922. Epub 2021 Mar 11. PMID: 33719970.
Copy Download .nbib Format: NLM
What are survivorship care plans failing to tell men after prostate cancer treatment?.

The Prostate

Choi Y, Smith KC, Shukla A, Blackford AL, Tran PT, Peairs KS, DeMarco TM, Choflet A, Farling K, Kelso M, Carducci MA, Mayonado N, Snyder CF.
PMID: 33755233
Prostate. 2021 May;81(7):398-406. doi: 10.1002/pros.24116. Epub 2021 Mar 23.

BACKGROUND: Survivorship care plans contain important information for patients and primary care physicians regarding appropriate care for cancer survivors after treatment. We describe the completeness of prostate cancer survivorship care plans and evaluate the concordance of follow-up recommendations with...

Cite
Choi Y, Smith KC, Shukla A, et al. What are survivorship care plans failing to tell men after prostate cancer treatment?. Prostate. 2021;81(7):398-406doi: 10.1002/pros.24116.
Choi, Y., Smith, K. C., Shukla, A., Blackford, A. L., Tran, P. T., Peairs, K. S., DeMarco, T. M., Choflet, A., Farling, K., Kelso, M., Carducci, M. A., Mayonado, N., & Snyder, C. F. (2021). What are survivorship care plans failing to tell men after prostate cancer treatment?. The Prostate, 81(7), 398-406. https://doi.org/10.1002/pros.24116
Choi, Youngjee, et al. "What are survivorship care plans failing to tell men after prostate cancer treatment?." The Prostate vol. 81,7 (2021): 398-406. doi: https://doi.org/10.1002/pros.24116
Choi Y, Smith KC, Shukla A, Blackford AL, Tran PT, Peairs KS, DeMarco TM, Choflet A, Farling K, Kelso M, Carducci MA, Mayonado N, Snyder CF. What are survivorship care plans failing to tell men after prostate cancer treatment?. Prostate. 2021 May;81(7):398-406. doi: 10.1002/pros.24116. Epub 2021 Mar 23. PMID: 33755233.
Copy Download .nbib Format: NLM
Showing 1213 to 1216 of 1216 entries